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The MAP kinase p38a is essential for neuronal
signaling. To better understand themolecular regula-
tion of p38a we used atomistic and molecular tech-
niques to determine the structural basis of p38a
regulation by the two neuronal tyrosine phospha-
tases, PTPSL/PTPBR7 (PTPRR) and STEP (PTPN5).
We show that, despite the fact that PTPSL and
STEP belong to the same family of regulatory pro-
teins, they interact with p38a differently and their
distinct molecular interactions explain their different
catalytic activities. Although the interaction of PTPSL
with p38a is similar to that of the previously
described p38a:HePTP (PTPN7) complex, STEP
binds and regulates p38a in an unexpected manner.
Using NMR and small-angle X-ray scattering data,
we generated a model of the p38a:STEP complex
and define molecular differences between its resting
and active states. Together, these results provide
insights intomolecular regulation of p38a by key reg-
ulatory proteins.
INTRODUCTION
The mitogen-activated protein kinases (MAPKs) p38, ERK, and
JNK are central to evolutionarily conserved signaling pathways
that are present in all eukaryotic cells. Each MAPK cascade is
activated in response to a diverse array of extracellular signals
and culminates in the dual phosphorylation of a threonine and
a tyrosine residue in the MAPK activation loop (De´rijard et al.,
1995). Dually phosphorylated MAPKs then phosphorylate both
cytosolic and nuclear targets, with the localization and duration
of MAPK activity determining the cellular response to the initial
extracellular signal. MAPK signal duration is finely controlled
by multiple phosphatases, including three kinase interaction
motif protein tyrosine phosphatases (KIM-PTPs): PTPSL/
PTPBR7 (PTPRR), STEP (PTPN5), HePTP (PTPN7 and LC-PTP)
(Hendriks et al., 1995; Lombroso et al., 1991; Zanke et al.,1612 Structure 21, 1612–1623, September 3, 2013 ª2013 Elsevier Lt1992). KIM-PTPs control MAPK signaling by two mechanisms:
(1) the KIM-PTP binds to an unphosphorylated MAPK to
sequester it in the cytosol (known as the resting-state complex);
and (2) the KIM-PTP dephosphorylates and inactivates a phos-
phorylated MAPK (known as the active-state complex) (Ta´rrega
et al., 2002; Xu et al., 2009).
Increasing evidence suggests a crucial role for MAPK
signaling in the central nervous system (CNS), and aberrant
phosphorylation within the CNS is associated with a multitude
of neurological disorders, including Alzheimer’s disease and
Parkinson’s disease (Kim and Choi, 2010). Correspondingly, an
additional layer of MAPK regulation is present within neurons.
Two KIM-PTPs, PTPSL and STEP, are expressed within discrete
regions of the CNS. PTPSL expression is highest in the cere-
bellum, while STEP is expressed in the hippocampus, striatum,
amygdale, and cortex (Chirivi et al., 2004; Lombroso et al.,
1993; Van Den Maagdenberg et al., 1999).
PTPSL, STEP, and the other KIM-PTP, HePTP, have a 17-
residue kinase interaction motif (KIM or D-motif) that is essential
for their interaction with ERK2 and p38 (Blanco-Aparicio et al.,
1999; Saxena et al., 1999). The KIM binds to a conserved binding
site that is formed by the hydrophobic docking groove and an
acidic patch named the common docking (CD) site (together
known as the KIM binding site or D-motif recruitment site) (Ta´r-
rega et al., 2002; Zhou et al., 2006). The KIM sequence is well
conserved across the KIM-PTP family. All three KIMs contain
basic residues, proposed to engage the CD site, upstream of a
hydrophobic motif (L-X-L-X-F, where F is a methionine in
STEP and PTPSL and a valine in HePTP; Figure 1A). Previously,
we used nuclear magnetic resonance (NMR) spectroscopy and
isothermal titration calorimetry (ITC) to define the interface of
HePTPKIM binding to p38a. We determined that the hydrophobic
motif occupies three hydrophobic pockets within the p38a
hydrophobic docking groove, while its basic residues interact
with the acidic patch (Francis et al., 2011a).
C terminal to the KIM is a region known as the kinase-speci-
ficity sequence (KIS), which is followed by a globular PTP cata-
lytic domain (CAT) (Eswaran et al., 2006; Mun˜oz et al., 2003;
Mustelin et al., 2005). Whereas the CAT is essential for dephos-
phorylation of the MAPK by the KIM-PTP, the importance of the
KIS remains ambiguous, especially because the KIS sequence is
divergent among the KIM-PTP family members. We previouslyd All rights reserved
Figure 1. The Mode of KIM Binding Is Conserved within the KIM-PTP Family
(A) Sequences of STEPKIMKIS, PTPSLKIMKIS, and HePTPKIMKIS and conservation as determined using ClustalW (Larkin et al., 2007). KIM residues are colored in
orange and blue. KIS residues are colored in gray.
(B) Constructs used in this study.
(C) 2D [1H,15N] TROSY spectrum of [2H,15N]-p38a (black) overlaid with the 2D [1H,15N] TROSY spectrum of [2H,15N]-p38a:PTPSLKIM (red; 1:8 molar ratio
p38a:PTPSLKIM).
(D) 2D [1H,15N] TROSY spectrum of [2H,15N]-p38a (black) overlaid with the 2D [1H,15N] TROSY spectrum of [2H,15N]-p38a:STEPKIM (red; 1:8 molar ratio
p38a:STEPKIM).
(E) Histograms show the combined 1H/15N CSPs versus p38a residue for the final titration points of each KIM-PTPKIM peptide with [
2H,15N]-p38a.
See also Figure S1.
Structure
MAPK:KIM-PTP Complexesshowed that the HePTPKIS is highly flexible and contributes
significantly to the interaction between HePTP and p38a, while
HePTPCAT does not interact with unphosphorylated p38a. This
was corroborated by small-angle X-ray scattering (SAXS) exper-
iments that showed that the p38a:HePTP resting-state complex
is elongated in solution (Francis et al., 2011a). Whether the
extensive KIS interaction, limited CAT interaction, and extended
resting-state conformation observed in p38a:HePTP are com-
mon features of all p38a:KIM-PTP resting-state complexes is
currently unknown.
Similar studies with a different MAPK, ERK2, revealed that the
ERK2:HePTP resting-state complex shares several of these fea-Structure 21, 1612–16tures. Aswith p38a, HePTPCAT does not interact with ERK2 in the
resting state, and the ERK2:HePTP resting-state complex is
extended in solution (Piserchio et al., 2012). However, phosphor-
ylation of ERK2 leads to a domain rearrangement in which
HePTPCAT rotates by nearly 180
, the ERK2:HePTP complex
compacts, and the HePTP catalytic site residue moves by
65 A˚ to allow for dephosphorylation of ERK2 (Francis et al.,
2011b). The flexibility of the HePTPKIS and the absence of an
interaction between ERK2 and HePTPCAT are critical to facilitate
this large rearrangement.
Here, we combined NMR spectroscopy, SAXS, ITC experi-
ments, and HADDOCK modeling to delineate the interaction of23, September 3, 2013 ª2013 Elsevier Ltd All rights reserved 1613
Figure 2. PTPSL and STEP Interaction with p38a
Histograms showing the combined 1H/15N CSP versus p38a residue for the following experiments: p38awith PTPSLKIM (1:8 molar ratio), PTPSLKIMKIS (1:3 molar
ratio), PTPSL (1:1 ratio; SEC purified), STEPKIM (1:8 molar ratio), STEPKIMKIS (1:8 molar ratio), STEP (1:1 ratio; SEC purified), and PSChimera (1:1 ratio; SEC
purified). Residues that form the p38a hydrophobic docking groove and the CD site are highlighted by blue and orange boxes, respectively. Residues with peak
line widths broadened beyond detection upon titration are colored in green. See also Figure S3.
Structure
MAPK:KIM-PTP Complexesp38a with STEP and PTPSL. In combination with experiments
conducted with HePTP, these studies serve as a detailed
atomic-level characterization of MAPK regulation by an entire
family of regulators—the KIM-PTP family. Our results reveal
key differences between the interactions of p38a with each
KIM-PTP. We show that the interaction of p38a with PTPSL is
closely related to the interaction of HePTP, whereas the interac-
tion of p38a with STEP is quite different and includes an unex-
pected contribution from STEPCAT.
RESULTS
KIM Binding to p38a Is Conserved within the KIM-PTP
Family
WeusedNMR spectroscopy to define the p38a binding interface
of the STEPKIM and PTPSLKIM peptides (constructs used in this
study are illustrated in Figure 1B). Each peptide was individually
titrated into [2H,15N]-p38a until binding was saturated (1:1, 1:3,
1:5, 1:8 molar ratio of p38a:peptide) and two-dimensional (2D)
[1H,15N] TROSY spectra were recorded (Figures 1C and 1D; Fig-
ure S1A available online). The fully saturated 2D [1H,15N] TROSY
spectra of p38a:PTPSLKIM and p38a:STEPKIM (100 mM [
2H,15N]-
p38a:800 mM peptide) are highly similar (Figure 1E; Figure S1B).
All peak shifts are in fast exchange and can be readily followed1614 Structure 21, 1612–1623, September 3, 2013 ª2013 Elsevier Ltwith the exception of three peaks that map to the MAPK-specific
insert (L262–Q264) and are broadened beyond detection
independent of ligand (Figure S1A). As expected, both peptides
caused significant chemical shift perturbations (CSPs) for
residues located in the KIM binding site, including helix aD, helix
aE, the aD–aE loop, the b7–b8 turn, loop 4, and the CD site
(Figure 2). Thus, like HePTPKIM, PTPSLKIM and STEPKIM engage
all three hydrophobic pockets and interact with the acidic patch,
demonstrating that the mode of KIM binding to p38a is
conserved within the KIM-PTP family.
However, there are small differences among the CSPs
induced by STEPKIM and PTPSLKIM. L164 in b8 exhibits the
largest CSP difference among the 2D [1H,15N] TROSY spectra
of p38a:PTPSLKIM and p38a:STEPKIM (Figure 1E; Figure S1B).
The N-terminal residues of the KIM (Ile in PTPSLKIM; Met in
STEPKIM) are the only residues not identical between the two
peptides; therefore, any differences between the two spectra
are a result of the differential interaction of this residue with
p38a. Based on the structure of ERK2:HePTPKIM, this residue
is immediately adjacent to the b7–b8 turn, further supporting
our NMR results (Zhou et al., 2006).
Although the KIM binding mode is conserved among the KIM-
PTPs, the HePTPKIM sequence is only 75% conserved when
compared with PTPSLKIM and STEPKIM (Figure 1A). This leadsd All rights reserved
Table 1. Thermodynamic and Dissociation Constants for p38a:KIM-PTP Domains Derived from ITC Experiments at 25C
Interaction Kd (nM) DH (kcal$mol
1) TDS (kcal$mol1) DG (kcal$mol1)
p38a: STEPKIM 3,567 ± 208 37.7 ± 2.5 30.2 ± 2.5 7.4 ± 0.1
p38a: STEPKIMKIS 1,340 ± 135 34.7 ± 1.4 26.6 ± 1.5 8.0 ± 0.1
p38a: STEP 577 ± 71 28.8 ± 2.0 20.3 ± 2.0 8.5 ± 0.1
p38a: STEPF274A/F281A 1,074 ± 105 24.2 ± 0.4 16.0 ± 0.4 8.2 ± 0.1
p38a: STEPF281A/I307A 1,062 ± 36 34.3 ± 1.1 26.2 ± 1.0 8.2 ± 0.1
p38a: STEPM285A/I307A 592 ± 106 27.6 ± 0.5 19 ± 0.3 8.5 ± 0.1
p38a: PTPSLKIM 2,840 ± 135 33.0 ± 1.7 25.4 ± 1.7 7.6 ± 0.1
p38a: PTPSLKIMKIS 1,527 ± 23 38.8 ± 6.1 30.8 ± 6.1 7.9 ± 0.1
p38a: PTPSL 382 ± 65 30.2 ± 1.5 21.4 ± 1.4 8.8 ± 0.1
p38a: PSChimera 309 ± 4 27.2 ± 0.7 18.3 ± 0.7 8.9 ± 0.0
See also Figure S2.
Structure
MAPK:KIM-PTP Complexesto changes in the chemical environment for residues within the
p38a KIM binding site, which are readily observed in the 2D
[1H,15N] TROSY spectra (Figure S1C). PTPSLKIM and STEPKIM
perturb nine more peaks than HePTPKIM (Francis et al., 2011a).
Compared to HePTPKIM, PTPSLKIM and STEPKIM interact differ-
entially with several residues within the hydrophobic binding
groove and loop 4, including N82, A111, L113, C119, L122,
D124, D125, V127, L130, S154, E160, C162, and L164 (Fig-
ure 1E). These NMR CSP experiments correspond well with
ITC measurements that showed PTPSLKIM and STEPKIM bind
p38a approximately two times tighter than does HePTPKIM (Ta-
ble 1; Figure S2).
An NMR View of the Interaction between PTPSL and
p38a
We expanded the NMR experiments to define the binding inter-
face of PTPSL with p38a. In this experiment, [2H,15N]-p38a was
incubated with unlabeled PTPSL, the 78 kDa p38a:PTPSL
complex was purified by size exclusion chromatography (SEC),
and a 2D [1H,15N] TROSY spectrum was immediately recorded
(Figure S3C).
Direct comparison of the 2D [1H,15N] TROSY spectra of free
and PTPSL-bound p38a reveals CSPs of 41 peaks, 36 in fast
exchange and 5 peaks with line widths broadened beyond
detection (N115, Q120, F129, L130, and S154; Figure 2). Like
PTPSLKIM, PTPSL perturbed residues clustered within the
hydrophobic binding groove and the acidic patch of p38a (Fig-
ure 2). Two peaks, N115 (line widths broadened beyond detec-
tion) and V127, are perturbed by full-length PTPSL but not by
PTPSLKIM, with additional peaks experiencing larger CSPs
(G110, D112, I116, K118, Q120, and Q310) (Figure 2). Corre-
spondingly, full-length PTPSL binds approximately seven times
tighter to p38a than does PTPSLKIM (Table 1; Figure S2).
The majority of the additional CSPs map to a region of p38a
that interacts with HePTPKIS (Francis et al., 2011a). Although
the PTPSLKIS and HePTPKIS sequences are only 50%
conserved, this region of p38a is thus also likely interacting
with PTPSLKIS. To determine whether a peptide composed of
the PTPSLKIM and PTPSLKIS sequences (i.e., PTPSLKIMKIS)
can recapitulate the binding of full-length PTPSL to p38a, we
titrated the PTPSLKIMKIS into [
2H,15N]-p38a, and a series of
2D [1H,15N] TROSY spectra were recorded (Figure S3B). Titra-Structure 21, 1612–16tion of a three-fold molar excess of the PTPSLKIMKIS peptide
(100 mM [2H,15N]-p38a:300 mM PTPSLKIMKIS) resulted in a
nearly identical 2D [1H,15N] TROSY spectrum as that of
p38a:PTPSL (Figure 2, Figure S3H). Differences include resi-
dues N115 and S154, which are broadened beyond detection
by full-length PTPSL but are either not perturbed (N115) or
undergo a large CSP (S154) with PTPSLKIMKIS, respectively
(Figure S3H). Furthermore, a direct comparison of the 2D
[1H,15N] TROSY spectra of p38a:PTPSLKIM with p38a:PTPSL-
KIMKIS shows larger CSPs for four residues (M109, K118,
E160, and L164), and three peaks (Q120, F129, and L130) are
broadened beyond detection by PTPSLKIMKIS but not by
PTPSLKIM (Figure S3H). Consistent with these results, the
PTPSLKIMKIS binds p38a approximately two times tighter than
does PTPSLKIM (Table 1; Figure S2).
The p38a:PTPSL Resting-State Complex Is Extended in
Solution
The interactions of PTPSLKIM, PTPSLKIMKIS, and PTPSL with
p38a are highly similar. PTPSL perturbed few residues outside
of the KIM binding site, confirming that the KIM is the essential
anchor for the interaction of PTPSL with p38a. Indeed, we
used NMR spectroscopy to probe the interaction of p38a with
PTPSLCAT, a construct lacking residues 332–360, which includes
the KIM; no interactions between p38a and isolated PTPSLCAT
were detected (Figures S4A and S4C). This is consistent with
previous results from NMR experiments that showed that the
isolated HePTPCAT did not interact with either p38a or ERK2
(Francis et al., 2011a; Piserchio et al., 2012).
Consequently, we used SAXS to determine the size and shape
of the p38a:PTPSL resting-state complex. The p38a:PTPSL
complex was purified by SEC, and SAXS data were recorded
at Beamline X9A at the National Synchrotron Light Source (Broo-
khaven National Laboratories). Using the Guinier approximation
of five independent SAXS samples, a radius of gyration (Rg) of
33.1 ± 0.5 A˚ was calculated for the p38a:PTPSL complex (Table
2; Figure 3A). A maximum particle dimension (Dmax) of 105 A˚ was
determined by analysis of the P(r) function (Table 2; Figures 3D
and 3E). These values for Rg and Dmax are highly similar to those
determined for the p38a:HePTP and ERK2:HePTP resting-state
complexes and demonstrate that, under resting conditions,
p38a and PTPSL adopt an extended conformation, with a rather23, September 3, 2013 ª2013 Elsevier Ltd All rights reserved 1615
Table 2. SAXS Analysis of p38a:PTPSL, p38a:STEP, and
pp38a:STEP Complexes
p38:PTPSL
p38:STEP
(Resting)
pp38:STEP
(Active)
Guinier approximation
Rg (A˚) 33.1 ± 0.5 29.9 ± 0.3 28.5 ± 0.3
P(r) function calculation
Q range (A˚1) 0.013–0.303 0.013–0.304 0.014–0.297
Rg (A˚) 34.1 29.8 28.2
Dmax (A˚) 105 95 80
Structure modeling
c 1.4 ± 0.1 1.9 ± 0.2 1.0 ± 0.1
NSD 1.30 ± 0.04 1.09 ± 0.03 1.00 ± 0.03
Structure
MAPK:KIM-PTP Complexeslimited interaction surface, consistent with the NMR CSP
experiments.
The p38a:STEP Resting-State Complex Is Compact
An equivalent SAXS measurement was performed for the p38a:
STEP resting-state complex. The Guinier approximation of four
independent SAXS samples was used to calculate an Rg of
29.9 ± 0.3 A˚, showing that the Rg of the p38a:STEP resting-state
complex is 3.0 A˚ smaller than that of the p38a:PTPSL and
p38a:HePTP resting-state complexes (Table 2; Figure 3B). To
analyze this difference in more detail, we determined the molec-
ular envelope of the p38a:STEP resting-state complex (Table 2;
Figures 3D and 3F). A Dmax of 95 A˚ was determined by analysis of
theP(r) function, which is10–15 A˚ shorter than the p38a:PTPSL
and p38a:HePTP complexes (Table 2; Figure 3D). Thus, the
p38a:STEP resting-state complex is more compact than both
the p38a:KIM-PTP and the ERK2:HePTP resting-state com-
plexes. Therefore, unlike PTPSL and HePTP, which have limited
interaction surfaces with p38a, this result suggested that STEP
may interact more extensively with p38a.
STEP Has Interactions with p38a Outside of the KIM
Binding Pocket
To test this hypothesis, we performed NMR CSP experiments
with full-length STEP and [2H,15N]-p38a. Here, [2H,15N]-p38a
was incubated with unlabeled STEP, the 78 kDa p38a:STEP
complex purified by SEC, and a 2D [1H,15N] TROSY spectrum
recorded (Figure S3F). Direct comparison of the 2D [1H,15N]
TROSY spectra of free and STEP-bound p38a reveals CSPs of
58 peaks, 40 in fast exchange and 18 with peak line widths
that are broadened beyond detection (Figure 2). As expected,
like STEPKIM, STEP perturbs residues in the p38a KIM binding
site (Figure 2). Surprisingly, STEP perturbed significantly more
residues in p38a than did STEPKIM and caused several additional
peaks to broaden beyond detection, decreasing the total num-
ber of peaks in the 2D [1H,15N] TROSY spectrum of STEP-bound
p38a (Figure 2). Direct comparison of the 2D [1H,15N] TROSY
spectra of p38a:STEPKIM and p38a:STEP reveals three addi-
tional residues (V30, M109, and L164) with CSPs and 18 addi-
tional peaks (D125, V127, Y132, I141, S154, D177, M179,
V183, A190, Q202, R220, L222, L247, K248, S254, R256,
H312, and E328) that are broadened beyond detection by full-1616 Structure 21, 1612–1623, September 3, 2013 ª2013 Elsevier Ltlength STEP (Figure S3I). Correspondingly, full-length STEP
binds approximately six times tighter to p38a than does STEPKIM
(Table 1; Figure S2). Mapping the additional perturbations
reveals a previously undetected p38a interaction surface (herein
referred to as the PTP site), which connects the p38a activation
loop to the MAPK-specific insert.
To corroborate our findings, we used a divide and conquer
approach. To determine whether the STEPKIS accounts for this
additional interaction, a peptide composed of the STEPKIMKIS
sequence was titrated into [2H,15N]-p38a, and a series of 2D
[1H,15N] TROSY spectra was recorded (Figure S3E). Interest-
ingly, the p38a:STEPKIMKIS spectrum (100 mM [
2H,15N]-
p38a:800 mM STEPKIMKIS) is similar to that of p38a:STEPKIM at
the same molar ratio (Figure 2; Figure S3I). Direct comparison
of the 2D [1H,15N] TROSY spectra of p38a:STEPKIM and p38a:
STEPKIMKIS reveals differences in seven residues: V30, M109,
and E160 show CSPs, while G85, D125, V127, and S154 are
broadened beyond detection (Figure S3I). Using ITC, we deter-
mined that STEPKIMKIS binds approximately two and a half times
tighter than does STEPKIM but two times weaker than full-length
STEP does (Table 1; Figure S2). Importantly, the STEPKIMKIS did
not affect residues within the PTP site (Figure 2). This suggests
that the additional changes in the NMR spectrum must be the
result of an interaction between the STEP catalytic domain
(STEPCAT) and p38a.
p38a:PSChimera Complex
To confirm that STEPCAT interacts directly with p38a, we gener-
ated a chimeric protein in which PTPSLKIMKIS was fused with
STEPCAT (herein referred to as the PSChimera; Figure 1B). The
PSChimera was expressed, purified, and incubated with
[2H,15N]-p38a. The p38a:PSChimera complex was then purified
by SEC, and a 2D [1H,15N] TROSY spectrum of the complex was
recorded (Figure S3G).
Within and around the p38a KIM binding site, the PSChimera
affected the p38a 2D [1H,15N] TROSY spectrum in a PTPSL-like
manner (Figure 2). Notably, additional changes in the p38a 2D
[1H,15N] TROSY spectrum, which correspond to peaks that
define the PTP site, were also identified (Figure 2). Thus, the
PSChimera, which has a PTPSLKIMKIS and a STEPCAT domain,
interacts in a PTPSL-like manner with its KIMKIS and in a
STEP-like manner at the PTP site. Minor differences between
the interaction of the PSChimera and STEP with p38a at the
PTP site include Q202 and K248, which are not broadened
beyond detection with PSChimera (K248 does experience a
small CSP). Similar to STEP, 17 peaks in the PTP site broaden
beyond detection with PSChimera, demonstrating that the
STEPCAT interaction with p38a is independent of the KIMKIS
sequence. Furthermore, NMR interaction studies showed that
titration of unlabeled, isolated STEPCAT (lacking residues 214–
243 including the KIM) with [2H,15N]-p38a results in nonspecific
interactions throughout the p38a surface—further reinforcing
the critical importance of KIM anchoring for p38a regulation
(Figures S4B and S4C). The chimeric protein has a slightly
higher binding affinity than does PTPSL or STEP for p38a
(Table 1). This binding affinity is the product of the PTPSLKIM,
which binds the tightest of the three KIM-PTPKIM peptides,
coupled with the additional binding strength afforded by the
STEPCAT interaction.d All rights reserved
Figure 3. The p38a:PTPSL and p38a:STEP
Resting-State Complex
(A) SAXS data (I(q) versus q) of the p38a:PTPSL
resting-state complex shown (black squares) with
error bars (gray lines). Error bars show the exper-
imental error based on circular averaging of the
2D solution scattering data; theoretical scattering
curve from ab initiomolecular envelope (red); inset,
Guinier plots for samples at 2.3 mg/ml and
4.0 mg/ml.
(B) SAXS data (I(q) versus q) of the p38a:STEP
resting-state complex shown (black squares) with
error bars (gray lines). Theoretical scattering curve
from the ab initio molecular envelope (red); inset,
Guinier plots for samples at 2.0 mg/ml and
4.0 mg/ml.
(C) Kratky plot of the p38a:PTPSL resting-state
SAXS data (green) and p38a:STEP resting-state
SAXS data (blue).
(D) P(r) function of the p38a:PTPSL resting-state
complex (green) and p38a:STEP resting-state
complex (blue).
(E) p38a:PTPSL ab initio molecular envelope in two
views rotated by 90 with the dimensions of the
envelope.
(F) The p38a:STEP ab initio molecular envelope in
two views rotated by 90 with the dimensions of
the envelope.
Structure
MAPK:KIM-PTP ComplexesDefining the p38a Binding Site on STEP
To define the p38a binding interface on STEP, we performed
reverse NMR experiments with [2H,15N]-STEP and unlabeled
p38a. We previously published the sequence-specific backbone
assignments of STEPCAT (Francis et al., 2013). The 2D [
1H,15N]
TROSY spectrum of STEP contains 30 additional peaks when
compared to that of STEPCAT, in agreement with the 31 addi-
tional N-terminal residues in STEP (Figure S4D). All new peaks
cluster around 8.0 ppm, a chemical shift range typical for un-
structured residues, suggesting that the KIM and KIS regions
of STEP are unstructured in the unbound state, identical to
what we have seen for HePTP (Figure S4D) (Francis et al.,
2011a). Last, the vast majority of peaks in the STEP 2D
[1H,15N] TROSY spectrum overlap perfectly with peaks in the
STEPCAT 2D [
1H,15N] TROSY spectrum, showing that the flexible
N-terminal residues in STEP do not interact with STEPCAT. This
allowed for the transfer of the STEPCAT sequence-specific back-
bone assignment to STEP.
Peaks corresponding to residues 244–253, the majority of he-
lix a0, have very different chemical shifts between STEP and
STEPCAT, indicating that the presence of the flexible N terminus
(residues 214–243) alters the chemical environment of residues
244–253. This is consistent with what was observed for HePTP,
in which helix a0 (residues 44–56) was also perturbed by the
presence of the N terminus, residues 15–43 (Francis et al.,
2011a). Previously, it was hypothesized that helix a0 must
change conformation for the regulatory Ser/Thr residue at the
N terminus of the helix to be phosphorylated (Mustelin et al.,
2005; Szedlacsek et al., 2001). These NMR studies show thatStructure 21, 1612–1623, September 3, 2013 ªthis hypothesis is correct and the pliability
of helix a0 is conserved within the KIM-
PTP family.To test the effects of p38a binding on STEP, the complex be-
tween [2H,15N]-STEP and unlabeled p38a was purified by SEC,
and a 2D [1H,15N] TROSY spectrum of the 78 kDa complex
was immediately collected (Figure S4E). Direct comparison of
the 2D [1H,15N] TROSY spectra of free and p38a-bound STEP re-
veals changes in 54 peaks, 22 of which are in fast exchange and
32with peak line widths broadened beyond detection (Figure 4A;
Figure S4E). Included in this total are 21 of the new peaks that
clustered around 8.0 ppm in the free STEP spectrum that are
broadened beyond detection or overlap with other peaks in the
2D [1H,15N] TROSY spectrum of the p38a:STEP complex. This
indicates, as expected, a strong involvement of the STEPKIM in
p38a binding. Additional new peaks unperturbed by p38a bind-
ing originate from STEPKIS residues that do not contribute to
p38a binding. Thirty-three perturbed peaks are in STEPCAT,
including residues in helix a10 (A263, E268, and K269), helix a20
(F274, L276, E277, A278, E279, F280, F281, and E282), the
b4–b7 loop (N376, I377, E378, E379, and M380), helix a4
(R478, T479, and F482), and helix a6 (T517, C518, Q520, and
H525) (Figure 4A). Other STEPCAT residues that are affected
include L254, A257, M285, N286, D294, T306, I307, G350,
V353, and the catalytically important Q516 (Figure 4A).
3D Model of the p38a:STEP Complex
We used the NMR data, which describe the interaction interface
of STEP on p38a and vice versa, together with surface acc-
essibility data to restrain the docking of STEP and p38a using
HADDOCK (the crystal structures of apo-p38a [1P38] and
STEPCAT [2BIJ] [de Vries et al., 2007; Dominguez et al.,2013 Elsevier Ltd All rights reserved 1617
Figure 4. STEPCAT Binds to the p38a Activation Loop and MAPK Insert Primarily through Helix a-2
0
(A) Histograms showing the combined 1H/15N CSP versus STEP residue for the interaction of p38a with [2H,15N]-STEP.
(B) Alignment of the four lowest energy HADDOCK structures of the p38a:STEPCAT complex. p38a is colored blue and STEPCAT is colored in shades of orange.
(C) Superposition of the lowest energy HADDOCK p38a:STEPCAT complex structure with the experimental SAXS molecular envelope of the p38a:STEP resting-
state complex; p38a (blue), KIM (green), and STEPCAT (orange).
See also Figure S4.
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MAPK:KIM-PTP Complexes2003; Eswaran et al., 2006; Wang et al., 1997] were used as
starting structures). Although the STEPCAT structure does not
include STEPKIMKIS residues (214–257), we have established—
using the PSChimera—that the STEPCAT interaction occurred in-
dependent of a specific KIMKIS sequence. Consequently, only
p38a residues affected by STEPCAT in both STEP and the PSChi-
mera were used as input for the HADDOCK calculations. The
lowest energy cluster produced by HADDOCK contained 76
structures with a root-mean-square deviation of 0.8 A˚. The four
lowest energy structures from this cluster are shown in Figure 4B.
In all HADDOCK models, STEP helix a20 binds to p38a between
the activation loop and the MAPK-specific insert. The interface
between the two proteins buries 2,125 ± 116 A˚2 of surface
area. To experimentally test the validity of the model, we
compared the calculated (determined using Hydropro; Ortega
et al., 2011) Rg of the lowest energy p38a:STEP HADDOCK
model (Rg = 29.2 A˚) with the experimentally determined Rg1618 Structure 21, 1612–1623, September 3, 2013 ª2013 Elsevier Lt(Rg = 29.9 A˚). The excellent consistency of the Rgs is further sup-
ported by the excellent fit of the lowest energy p38a:STEP
HADDOCK model into the molecular envelope determined for
the p38a:STEP resting-state complex (NSD = 1.7; Figure 4C).
Additionally, modeling the KIM peptide into the KIM binding
site of p38a (based on the ERK2:HePTPKIM crystal structure;
Zhou et al., 2006) results in, as expected, a further improved
model of the p38a:STEP resting-state complex (Rg = 30.1 A˚;
Dmax = 92 A˚). This model, which comprises every component
of the complex but the STEPKIS, superimposes even better
with the p38a:STEP molecular envelope (NSD = 1.5; Figure 4C)
(Kozin and Svergun, 2001).
To further verify the model of the p38a:STEP resting-state
complex, we generated a number of STEP mutants that are pre-
dicted to lead to changes in binding affinity because themutated
residues are directly involved in the p38a:STEP interaction.
Indeed, mutation of residue F281 in helix a20, and to a lesserd All rights reserved
Figure 5. The p38a:STEP Active-State Complex Is More Compact Than the Resting-State Complex
(A) Experimental SAXS data (I(q) versus q) of the p38a:STEP active-state complex shown as black squares with error bars as gray lines. Error bars show the
experimental error based on circular averaging of the 2D solution scattering data; theoretical scattering curve from ab initio molecular envelope (red); inset,
Guinier plots for samples at 3.3 mg/ml and 6.1 mg/ml.
(B) Kratky plot.
(C) P(r) function of the p38a:STEP active-state complex (blue) overlaid with resting-state complex (red).
(D) Averaged ab initio molecular envelope; two views rotated by 90 with the dimensions of the envelope.
Structure
MAPK:KIM-PTP Complexesextent M285 and I307, showed a reduction of the binding affinity,
clearly showing that helix a20 is important for the interaction of
STEP with p38a and further confirming the HADDOCK model
(Table 1).
The p38a:STEP Active-State Complex
We have shown that STEPCAT, when tethered via the KIM, inter-
acts with p38a and perturbs residues in the p38a activation loop.
However, this does not imply that STEP is poised and ready to
efficiently dephosphorylate p38a. In fact, in the HADDOCK
p38a:STEP resting-state complex model the STEP active site
cysteine is35 A˚ away from the p38a phosphorylation loop tyro-
sine. Therefore, a domain arrangement must occur between the
resting and active states of the p38a:STEP complex to properly
position STEPCAT for dephosphorylation of p38a.
To verify that a domain rearrangement occurs between the
active and resting states of the p38a:STEP complex, we used
SAXS to determine the size and shape of the p38a:STEP
active-state complex (Akella et al., 2010; Nielsen and Schwalbe,
2011). p38a was dually phosphorylated in vitro using a constitu-
tively active mutant of MKK6. Phosphorylated p38a was incu-Structure 21, 1612–16bated with a substrate-trapping mutant of STEP (C472S/
T306D), the complex purified by SEC, and SAXS data recorded
(Figure 5A). Using the Guinier approximation of six independent
SAXS samples, an Rg of 28.5 ± 0.3 A˚ was calculated for the
p38a:STEP active-state complex (Table 2; Figure 5A). This Rg
is 1.5 A˚ smaller than the Rg of the resting-state complex. More
striking, the Dmax of the active-state complex, 80 A˚, is 15 A˚
shorter than the resting-state complex (Table 2; Figures 5C
and 5D). These data show that the p38a:STEP active-state com-
plex is more compact than the resting-state complex and sup-
port that a domain rearrangement occurs between the resting
and active states of the p38a:STEP complex. Thus, although
STEPCAT interacts with p38a in the resting state, it is not properly
positioned for dephosphorylation of p38a.
DISCUSSION
Our current understanding of MAPK regulation by their regu-
latory proteins at the molecular level is extremely limited
because these essential signaling complexes have proven
exceedingly difficult to investigate using traditional structural23, September 3, 2013 ª2013 Elsevier Ltd All rights reserved 1619
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MAPK:KIM-PTP Complexesapproaches. Years of efforts to crystallize MAPK:KIM-PTP com-
plexes have not been successful, and their large molecular
weights, 80 kDa, make NMR analysis onerous. To circumvent
these problems, we examined the binding of each domain of
STEP and PTPSL to p38a using NMR CSP and ITC experiments
and then determined the overall molecular shape of the com-
plexes using SAXS. Using this approach, we show that, despite
having similar KIM-peptide interactions and overall binding affin-
ities with p38a, the p38a:PTPSL and p38a:STEP resting-state
complexes are surprisingly different as a result of an additional
interaction of the STEP catalytic domain with p38a. These
studies, in combination with complementary studies previously
performed between p38a and HePTP, provide a detailed inves-
tigation of MAPK regulation by an entire family of regulators
(Francis et al., 2011a).
Using NMR experiments, we show that the mode of KIM bind-
ing to p38a is conserved among the KIM-PTP family. Uniformly,
PTPSLKIM, STEPKIM, and HePTPKIM engaged residues within the
three hydrophobic pockets and perturbed residues at the CD
site. In contrast, crystal structures of p38a bound to KIM pep-
tides of the activating kinases, MKK3b and MKK6, reveal a
different mode of binding in which only hydrophobic pockets
FA and FB are engaged and an extensive electrostatic interac-
tion with the CD site is absent (Chang et al., 2002; Garai et al.,
2012). This demonstrates a critical point in MAPK selectivity;
the mechanism of KIM binding to p38a is different for each class
of regulators (i.e., MAPKKs versus KIM-PTPs).
Based on NMR and SAXS data, the interaction of resting-state
p38awith PTPSL is similar to that described previously between
p38a and HePTP. However, the p38a:PTPSL and p38a:HePTP
interactions are not identical. One key feature of the p38a:HePTP
interaction, the extensive interaction between p38a and the
HePTPKIS, is not observed between p38a and the PTPSLKIS
(Francis et al., 2011a). Despite the limited interaction surface
between p38a and PTPSL, PTPSL binds p38a nearly six times
tighter than HePTP does. Recently published in vitro phospha-
tase assays showed that although HePTP and PTPSL can both
readily dephosphorylate p38a, PTPSL is the most efficient
p38a phosphatase of all tested (Zhang et al., 2011). This is likely
the product of (1) the highest affinity interaction with p38a among
the KIM-PTPs and (2) the limited interaction outside of the KIM,
imposing minimal constraints on the flexibility and movement
of the PTPSLCAT.
In contrast, the p38a:STEP resting-state complex is more
compact than the other two p38a:KIM-PTP resting-state com-
plexes because of an additional previously unidentified interac-
tion between STEPCAT and p38a. In the resting-state complex,
STEPCAT occludes a pocket on p38a formed between the
MAPK insert and the C lobe that has been shown to bind allo-
steric signaling molecules that are known activators of the
p38a cascade, such as fatty acids (Diskin et al., 2008; Nony
et al., 2005; Perry et al., 2009). Binding of certain lipid-based
molecules to this pocket has been shown to promote autophos-
phorylation and activation of p38a in vitro (Gills et al., 2007; Tza-
rum et al., 2012). STEP regulates p38a at the site of extrasynaptic
glutamate receptors, where overactivation of the kinase leads to
the production of proapoptotic signals culminating in neuronal
cell death (Poddar et al., 2010). Therefore, STEP may have
adapted several means to suppress p38a activity in the resting1620 Structure 21, 1612–1623, September 3, 2013 ª2013 Elsevier Ltstate. First, by binding strongly to the KIM binding site, STEP
prevents upstream activating kinases from promiscuously bind-
ing and activating p38a. Second, by blocking access to the
MAPK insert pocket, through the STEPCAT interaction, STEP
can prevent the binding of allosteric signaling molecules that
induce autoactivation of p38a.
The orientation of STEPCAT in the p38a:STEP resting-state
complex is not conducive to dephosphorylation of the tyrosine
residue in the p38a phosphorylation loop and significant rotation
of STEPCAT is necessary to properly position the active site
for catalysis. This domain rearrangement is evident when
comparing SAXS data of the resting and active states of the
p38a:STEP complex. A study conducted by Zhang et al. showed
that STEP is significantly less efficient than PTPSL and HePTP
at dephosphorylating p38a. The kcat for the STEP-catalyzed
dephosphorylation of p38a is 20-fold lower than those for
PTPSL or HePTP, showing that it is likely easier to move the
flexibly tethered HePTPCAT and PTPSLCAT than moving the
‘‘trapped’’ (i.e., p38a-bound) STEPCAT (Balasu et al., 2009;
Zhang et al., 2011).
Taken together, these results provide fundamental insights
into the molecular basis of p38a regulation by the neuronal
KIM-PTPs. We have identified how STEP prevents promiscuous
activation of p38a by blocking access to the MAPK insert
pocket. Because p38a has been implicated in the pathogenesis
of numerous neurological disorders, these findings could facili-
tate the development of new drug therapies to treat these
disorders.EXPERIMENTAL PROCEDURES
Peptide and Protein Preparation
The PTPSLKIM peptide (IGLQERRGSNVSLTLDM), STEPKIM (MGLQERR
GSNVSLTLDM), and STEPKIMKIS (MGLQERRGSNVSLTLDMCTPGCNEEGFG
YLVSPREESAHEYLLS) were synthesized, HPLC purified, and verified by
mass spectrometry (MS) (>98% purity; Biosynthesis).
Expression and purification of unphosphorylated p38a was carried out as
previously described (Francis et al., 2011a). PTPSL (residues 332–655),
PTPSLCAT (residues 361–655), STEP (residues 214–539), STEPCAT (residues
244–539), and PSChimera (PTPSL residues 332–373 with STEP residues
257–539; gene synthesized by DNA 2.0) were expressed and purified using
the protocol previously described in detail for STEPCAT (Francis et al., 2013).
STEP (residues 214–539) mutants F274A/F281A, F280A/I307A, and M285A/
I307A were produced by quick-change mutagenesis.
The PTPSLKIMKIS (residues 332–373) was subcloned into a derivative of the
pET28 vector that includes an N-terminal His6-tag and a TEV protease recog-
nition sequence (Peti and Page, 2007). The expression vector was trans-
formed into BL21-(DE3) RIL E. coli cells (Invitrogen). Cultures were grown in
Luria broth at 37C with shaking at 250 rpm until reaching an optical density
(OD600) between 0.6 and 0.8, at which point expression was induced by the
addition of 1.0 mM isopropylthio-b-D-galactoside (IPTG, final concentration).
The cultures were grown for an additional 3 hr at 37C with shaking at
250 rpm. The cells were harvested by centrifugation (6,000 3 g, 12 min,
4C) and stored at 80C until purification. All buffers and glassware used
for purification were autoclaved prior to purification. For purification, cell pel-
lets were resuspended in lysis buffer (50 mM Tris [pH 8.0], 500 mM NaCl,
5 mM imidazole, 0.1% Triton X-1000, and cOmplete EDTA-free protease in-
hibitor cocktail tablets; Roche) and lysed by high-pressure homogenization
(Avestin C3 Emulsiflex). The bacterial lysate was cleared by centrifugation
(35,000 3 g, 40 min, 4C). After filtration, the supernatant was loaded onto
a 5 ml HisTrap HP column (GE Healthcare) equilibrated with Buffer A
(50 mM Tris [pH 8.0], 500 mM NaCl, and 5 mM imidazole). Protein was eluted
from the column using a 5–500 mM imidazole gradient over 20 columnd All rights reserved
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incubation with TEV protease during overnight dialysis in 50 mM Tris
(pH 8.0), 500 mM NaCl at 4C. The TEV protease, the His6-tag, and uncleaved
protein were removed using a second IMAC step. Final purification was
achieved using size exclusion chromatography (SEC) equilibrated in 50 mM
Tris (pH 6.8), 500 mM NaCl. The molecular weight of the purified peptide
was verified by electrospray-ionization MS.
All unlabeled, purified proteinswere stored at80Cuntil use, at which point
they were thawed and equilibrated in the appropriate buffer using SEC. All
labeled proteins for NMR analysis were purified within 24 hr of data acquisition
and stored on ice. PTPSLKIM, STEPKIM, and STEPKIMKIS peptides were solubi-
lized in the appropriate buffer prior to the experiment. The final protein buffer
was dependent on the experiment performed. For ITC experiments, the final
SEC purification was performed in ITC buffer (10 mM Tris pH 7.5, 150 mM
NaCl, 0.1 mM EDTA, 0.5 mM TCEP); for NMR and SAXS experiments, the final
SEC purification was performed in NMR buffer (50 mM HEPES [pH 6.8],
150 mM NaCl, 5 mM dithiothreitol).
NMR Sample Preparation
[2H,15N]-p38a (Vogtherr et al., 2005) and [2H,15N]-STEP were expressed in M9
media supplemented with 15NH4Cl (1 g/l) in 99% D2O and purified as previ-
ously described. PTPSLKIM, PTPSLKIMKIS, STEPKIM, or STEPKIMKIS peptides
were added to [2H,15N]-p38a (100 mM p38a) in the following molar excesses:
PTPSLKIM (1:1 and 1:8 molar ratios, p38:peptide), PTPSLKIMKIS (1:1 and 1:3
molar ratios, p38:peptide), STEPKIM (1:1, 1:3, 1:5, and 1:8 molar ratios,
p38:peptide), and STEPKIMKIS (1:1, 1:3, 1:6, and 1:8 molar ratios, p38:peptide).
PTPSLCAT and STEPCAT were added to [
2H,15N]-p38a (100 mM p38a) in a
twofold molar excess (0.1 mM [2H,15N]-p38a:0.2 mM PTPSLCAT or STEPCAT).
For p38a:KIM-PTP complex formation, [2H,15N]-p38a was incubated with
either PTPSL, STEP, or PSChimera (1:1 molar ratio) on ice for 45 min and pu-
rified using SEC (Superdex 75 26/60, NMR buffer). Each p38a:KIM-PTP com-
plex elutes at the position expected for the p38a:KIM-PTP heterodimer. Each
[2H,15N]-p38a:KIM-PTP complex was concentrated to 0.1 mM and stored on
ice (<8 hr) until NMR data acquisition. For the p38a:[2H,15N]-STEP complex
formation, [2H,15N]-STEP was incubated with p38a (1:1 molar ratio) on ice
for 45 min and purified using SEC (Superdex 75 26/60, NMR buffer). The
p38a:[2H,15N]-STEP complex was concentrated to 0.1 mM and stored on
ice (<2 hr) until NMR data acquisition. A 2D [1H,15N]-TROSY spectrum was re-
corded for all samples described above. All NMR experiments were performed
at 298 K on a Bruker Advance 800 MHz spectrometer equipped with a TCI
HCN z-gradient cryoprobe. NMR samples were prepared in NMR buffer in
90% H2O/10% D2O. The NMR spectra were processed with Topspin 2.1/
3.0/3.1 (Bruker) and analyzed using CARA (http://cara.nmr.ch).
Chemical Shift Perturbation Studies
The p38a:STEPKIM and p38a: PTPSLKIM peptide titration series (1:1, 1:3, 1:5,
and 1:8 ratios, p38a:STEPKIM) were used to follow chemical shift changes in
p38a upon peptide or protein binding. Nearly all peaks showed fast exchange
and thus could be easily tracked. The observed trajectory of each peak was
applied to the analysis of the KIMKIS peptides (PTPSLKIMKIS and STEPKIMKIS)
and the full-length complexes (PTPSL, STEP, and PSChimera), allowing for
high certainty of peak assignments of p38a in the bound conformations. All
chemical shift differences (Dd) were calculated using
DdðppmÞ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
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
DdN
10
2s
:
To allow for direct comparison across all CSP experiments, we used iden-
tical cut-off CSPs as in the HePTP NMR experiments; small CSP 0.07–0.103
ppm, medium CSP 0.104–0.131 ppm, and large CSP R0.132 (Francis et al.,
2011a).
HADDOCK Calculations
HADDOCK was used to dock p38a and STEP using ambiguous NMR-derived
restraints. p38a (PBDID 1P38) and STEP (PBDID 2BIJ) were used as starting
input. Active residues were defined as those that undergo a CSP and have
high solvent accessibility in the unbound protein structure (p38a residues:
177, 179, 183, 222, 248, 254, and 256; STEP residues: 263, 268, 269, 274,Structure 21, 1612–16277, 278, 279, 281, 282, 285, 286, 294, 306, 307, 377, 378, 379, 516, 517,
and 518). Passive residues have a CSP but low solvent accessibility (p38a res-
idues: 190, 195, 247, 255, and 328; STEP residues: 276, 280, 350, 353, 376,
380, 478, 479, 482, 520, and 525). CSPs were the only experimental restraint
type used in the HADDOCK calculation and default settings were used for all
docking steps, as used by the easy interface of the HADDOCK web server
(http://haddock.science.uu.nl/enmr/services/HADDOCK).
Isothermal Titration Calorimetry
ITC experiments were performed at 25C using a VP-ITC microcalorimeter
(Microcal). Titrant (10 ml per injection) was injected into the sample cell over
a period of 20 s with a 250 s interval between titrations to allow for complete
equilibration and baseline recovery. Twenty-eight injections were delivered
during each experiment, and the solution in the sample cell was stirred at
307 rpm to ensure rapid mixing. To determine the thermodynamic parameters
(DH, DS, and DG) and binding constants (K) of the p38a:PTPSLKIM,
p38a:PTPSL, and p38a:STEP interactions, PTPSLKIM, PTPSL, and STEP
were titrated into the p38a. To determine the same parameters for the p38a:
STEPKIM, p38a:PTPSLKIMKIS, p38a:STEPKIMKIS, and p38a:PSChimera interac-
tion, p38a was titrated into the protein. For all titrations the concentrations
were slightly varied to ensure independence of the Kd from the protein/peptide
concentrations. Data were analyzed with a one-site binding model assuming a
binding stoichiometry of 1:1 using Origin 7.0 software. A nonlinear least-
squares algorithm and the titrant and sample cell concentrations were used
to fit the heat flow per injection to an equilibrium binding equation, providing
values of the stoichiometry (n), change in enthalpy (DH), and binding constant
(K). All data were repeated in triplicate.
Small-Angle X-Ray Scattering
For the resting-state p38a: PTPSL and p38a:STEP complexes, purified, un-
phosphorylated p38a was incubated in a 1:1 molar ratio with purified
PTPSL331–655 and/or purified STEP214–539 on ice for 30 min and the complexes
purified using SEC (Superdex 75 26/60, NMR buffer). To form the active-state
complex of p38a:STEP, purified, dually phosphorylated p38a was incubated
in a 1:1 molar ratio with purified STEP214–539 T306D/C472S on ice for
30 min and the complex was purified using SEC (Superdex 75 26/60, NMR
buffer). For p38a:PTPSL, data were collected on samples at 0.4, 0.8, 1.6,
2.3, and 4.0 mg/ml. For resting-state p38a:STEP, data were collected on sam-
ples at 1.0, 2.0, and 4.0 mg/ml. For active-state p38a:STEP, data were
collected on samples at 0.8, 3.3, and 6.1 mg/ml. All samples were prepared
within 48 hr of data acquisition and stored on ice at 4C. All samples were
filtered (0.02 mM filter, Whatman) immediately prior to data collection. All
data were recorded at beamline X9 at the National Synchrotron Light Source
(NSLS) using a Dectris pilatus 300k (p38a:PTPSL and active-state p38a:STEP;
3.4 m distance from the sample for SAXS) or a MarCCD 165 (resting-state
p38a:STEP; 3.4 m distance from the sample for SAXS) and a Photonic
Science CCD (0.47 m from the sample for WAXS) detector. Twenty microliters
of sample was continuously flowed through a 1 mm diameter capillary
and exposed to an X-ray beam for 30 s (p38a:PTPSL), 60 s (active-state
p38a:STEP), or 180 s (resting-state p38a:STEP). Normalization for beam in-
tensity, buffer subtraction, and merging of the data from both detectors was
carried out using PRIMUS (Konarev et al., 2003). A Guinier approximation,
I(q) = I(0)exp(q2Rg2 / 3), where a plot of ln[I(q)] and q2 is linear for q <
1.3/Rg, was performed on at least four independent scattering trials and aver-
aged to determine the radius of gyration. The linearity of the Guinier region and
the intensity at zero scattering angle, I(0), were used to validate that all sam-
ples were monodisperse in solution. I(0)/c, where c is concentration, was
consistent for all measurements for a single complex. GNOM (Svergun,
1992) was used to determine the pair-distribution function, P(r), for each com-
plex. Twenty-four envelopes were generated for each complex using
GASBOR (Svergun et al., 2001) and were aligned and averaged using the
DAMAVER program suite (Volkov and Svergun, 2003).
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